Johnson & Johnson is scheduled to report quarterly earnings on October 13, 2026, with analysts expecting earnings per share of $2.96, a 5.71% increase from the same quarter a year earlier, on revenue of $25.36 billion, also up 5.71% year over year. For the full year, the Zacks Consensus Estimates project earnings of $11.61 per share and revenue of $101.13 billion, representing changes of +7.6% and +7.37%, respectively, from the preceding year. Over the past month, the Zacks Consensus EPS estimate has fallen 0.04%, and Johnson & Johnson currently carries a Zacks Rank of #3 (Hold). The stock last closed at $270.22, a gain of 1.1% that trailed the S&P 500's daily gain of 1.14%, while the Dow added 0.61% and the Nasdaq gained 1.69%. Johnson & Johnson trades at a Forward P/E ratio of 23.05, a premium to the industry average of 15.67, and carries a PEG ratio of 2.55 versus an average of 1.98 for Large Cap Pharmaceuticals stocks.
Johnson & JohnsonJ&J sets its Q3 2026 earnings date with consensus EPS of $2.96 and revenue of $25.36B, but no actual results or new development — just scheduling and analyst estimates.
